{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:53:29Z","timestamp":1782255209245,"version":"3.54.5"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,15]]},"DOI":"10.2169\/internalmedicine.3038-19","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T22:02:47Z","timestamp":1564524167000},"page":"3323-3329","source":"Crossref","is-referenced-by-count":15,"title":["Inflammatory Cerebellar PML with a CD4\/CD8 Ratio of 2.9 Showed a Favorable Prognosis in a Patient with Rheumatoid Arthritis"],"prefix":"10.2169","volume":"58","author":[{"given":"Ryusei","family":"Nishigori","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan"},{"name":"Department of Neurology, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Warabi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Shishido-Hara","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Tokyo Medical University, Japan"},{"name":"Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nakamichi","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Tokyo Metropolitan Neurological Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komori","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Isozaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Neurological Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90: e1815-e1821, 2018.","DOI":"10.1212\/WNL.0000000000005529"},{"key":"2","unstructured":"2. Nishiyama S, Misu T, Shishido-Hara Y, et al. Fingolimod-associated PML with mild IRIS in MS: a clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5: e415, 2018."},{"key":"3","unstructured":"3. Ishii J, Shishido-Hara Y, Kawamoto M, et al. A punctate magnetic resonance imaging pattern in a patient with systemic lupus erythematosus is an early sign of progressive multifocal leukoencephalopathy: a clinicopathological study. Intern Med 57: 2727-2734, 2018."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wattjes MP, Wijburg MT, Vennegoor A, et al. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 87: 879-884, 2016.","DOI":"10.1136\/jnnp-2015-311411"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123: 235-245, 2012.","DOI":"10.1007\/s00401-011-0900-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71: 604-617, 2012.","DOI":"10.1097\/NEN.0b013e31825caf2c"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Himedan M, Camelo-Piragua S, Mills EA, Gupta A, Aburashed R, Mao-Draayer Y. Pathologic findings of chronic PML-IRIS in a patient with prolonged PML survival following natalizumab treatment. J Investig Med High Impact Case Rep 5: 2324709617734248, 2017.","DOI":"10.1177\/2324709617734248"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sanjo N, Kina S, Shishido-Hara Y, et al. Progressive multifocal leukoencephalopathy with balanced CD4\/CD8 T-Cell infiltration and good response to mefloquine treatment. Intern Med 55: 1631-1635, 2016.","DOI":"10.2169\/internalmedicine.55.6051"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Shishido-Hara Y. Progressive multifocal leukoencephalopathy: dot-shaped inclusions and virus-host interactions. Neuropathology 35: 487-496, 2015.","DOI":"10.1111\/neup.12203"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ryschkewitsch CF, Jensen PN, Major EO. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J Clin Virol 57: 243-248, 2013.","DOI":"10.1016\/j.jcv.2013.03.009"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Akagawa Y, Ueno A, Ikeda J, Ishii W, Shishido-Hara Y, Sekijima Y. [Two patients with progressive multifocal leukoencephalopathy with immune response against JC virus showing good long-term outcome by combination therapy of mefloquine, mirtazapine, and risperidone]. Rinsho Shinkeigaku 58: 324-331, 2018 (in Japanese, Abstract in English).","DOI":"10.5692\/clinicalneurol.cn-001166"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80: 1430-1438, 2013.","DOI":"10.1212\/WNL.0b013e31828c2fa1"},{"key":"13","unstructured":"13. Shishido-Hara Y, Yazawa T, Nagane M, et al. JC virus inclusions in progressive multifocal leukoencephalopathy: scaffolding promyelocytic leukemia nuclear bodies grow with cell cycle transition through an S-to-G2-like state in enlarging oligodendrocyte nuclei. J Neuropathol Exp Neurol 73: 442-453, 2014."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shishido-Hara Y, Ichinose S, Higuchi K, Hara Y, Yasui K. Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol 78: 9890-9903, 2004.","DOI":"10.1128\/JVI.78.18.9890-9903.2004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sanjo N, Nose Y, Shishido-Hara Y, et al. A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy. J Neurol 266: 369-377, 2019.","DOI":"10.1007\/s00415-018-9140-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_3038-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T03:45:56Z","timestamp":1573875956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_3038-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":15,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3038-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}